Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation

Hiromichi Yamane, Nobuaki Ochi, Masayuki Yasugi, Takayuki Tabayashi, Tomoko Yamagishi, Yasumasa Monobe, Akiko Hisamoto, Katsuyuki Kiura, Nagio Takigawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalOncoTargets and Therapy
Volume6
DOIs
Publication statusPublished - 2013

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Pleural Effusion
Mutation
Pemetrexed
Exons
Drug Therapy
Sequence Deletion
Carboplatin
Threonine
Epidermal Growth Factor Receptor
Methionine
Protein-Tyrosine Kinases
Adenocarcinoma
Thorax
Therapeutics
Tomography
Lung
ErbB Receptors
Neoplasms

Keywords

  • Docetaxel
  • EGFR mutation
  • Non-small-cell lung cancer
  • Pretreatment mutation
  • T790M

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Yamane, H., Ochi, N., Yasugi, M., Tabayashi, T., Yamagishi, T., Monobe, Y., ... Takigawa, N. (2013). Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. OncoTargets and Therapy, 6, 155-160. https://doi.org/10.2147/OTT.S41797

Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. / Yamane, Hiromichi; Ochi, Nobuaki; Yasugi, Masayuki; Tabayashi, Takayuki; Yamagishi, Tomoko; Monobe, Yasumasa; Hisamoto, Akiko; Kiura, Katsuyuki; Takigawa, Nagio.

In: OncoTargets and Therapy, Vol. 6, 2013, p. 155-160.

Research output: Contribution to journalArticle

Yamane, H, Ochi, N, Yasugi, M, Tabayashi, T, Yamagishi, T, Monobe, Y, Hisamoto, A, Kiura, K & Takigawa, N 2013, 'Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation', OncoTargets and Therapy, vol. 6, pp. 155-160. https://doi.org/10.2147/OTT.S41797
Yamane, Hiromichi ; Ochi, Nobuaki ; Yasugi, Masayuki ; Tabayashi, Takayuki ; Yamagishi, Tomoko ; Monobe, Yasumasa ; Hisamoto, Akiko ; Kiura, Katsuyuki ; Takigawa, Nagio. / Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. In: OncoTargets and Therapy. 2013 ; Vol. 6. pp. 155-160.
@article{861a3e01523b4128822ea1d6a8abb331,
title = "Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation",
abstract = "A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.",
keywords = "Docetaxel, EGFR mutation, Non-small-cell lung cancer, Pretreatment mutation, T790M",
author = "Hiromichi Yamane and Nobuaki Ochi and Masayuki Yasugi and Takayuki Tabayashi and Tomoko Yamagishi and Yasumasa Monobe and Akiko Hisamoto and Katsuyuki Kiura and Nagio Takigawa",
year = "2013",
doi = "10.2147/OTT.S41797",
language = "English",
volume = "6",
pages = "155--160",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation

AU - Yamane, Hiromichi

AU - Ochi, Nobuaki

AU - Yasugi, Masayuki

AU - Tabayashi, Takayuki

AU - Yamagishi, Tomoko

AU - Monobe, Yasumasa

AU - Hisamoto, Akiko

AU - Kiura, Katsuyuki

AU - Takigawa, Nagio

PY - 2013

Y1 - 2013

N2 - A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.

AB - A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.

KW - Docetaxel

KW - EGFR mutation

KW - Non-small-cell lung cancer

KW - Pretreatment mutation

KW - T790M

UR - http://www.scopus.com/inward/record.url?scp=84875042147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875042147&partnerID=8YFLogxK

U2 - 10.2147/OTT.S41797

DO - 10.2147/OTT.S41797

M3 - Article

C2 - 23493804

AN - SCOPUS:84875042147

VL - 6

SP - 155

EP - 160

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -